Busi Pharmaceutical: Wholly-owned subsidiary obtains registration certificate for Oseltamivir Phosphate Capsules drug.

Boai Pharmaceutical announced that its wholly-owned subsidiary, Shaanxi Boai High-Tech Pharmaceutical Co., Ltd., has recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for Oseltamivir Phosphate Capsules. The drug is mainly used for the treatment of type A and type B influenza in adults and children aged 1 year and above, as well as for the prevention of type A and type B influenza in adults and adolescents aged 13 and above. The annual sales of physical drug stores in Chinese cities from 2022 to 2024 are 152 million yuan, 824 million yuan, and 776 million yuan, respectively. As of the disclosure date of the announcement, the company has invested approximately 12.9612 million yuan in research and development expenses for this project.